Agenda BBS Spring Conference 2011 Comparative Quantitative Assessments: Benefit-Risk & Effectiveness PDF
Chrissie Fletcher, Industry Perspective on Comparative Effectiveness Research (CER) and the impact of Health Technology Assessment (HTA) in Europe
Melvin (Skip) Olson, Some Issues with Indirect Comparisons
Friedhelm Leverkus, Health Care Reform in Germany and Update on IQWiG Requirements
John Doyle, Effect of Comparative Effectiveness Research on Drug Development Innovation: a 360° Appraisal and Summary Discussion
Deborah Ashby, Current Methodological Approaches to Benefit-Risk Decision-Making
John Ferguson, Structured Benefit-Risk Optimization (BRO): State-of-the-art and Role of Fully Quantitative Decision Support Tools
Michael Forstner, Considerations for Implementing a Quantitative Benefit-Risk Assessment
Richard Nixon, Benefit-Risk Assessment of Multiple Sclerosis Treatments: Lessons Learnt in the use of Multi-Criteria Decision Analysis
John Doyle, Convergence of CER and BRA and Concluding Summary Discussion
Sorry, the comment form is closed at this time.